|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,318,191: Solid Dispersions of Pharmaceutical Compounds
U.S. Patent 11,318,191, granted on May 3, 2022, describes solid dispersions of pharmaceutical compounds designed to improve bioavailability. The patent, assigned to Janssen Pharmaceutica NV, covers specific formulations of compounds with a certain solubility parameter and their preparation. The technology targets challenges associated with poorly soluble active pharmaceutical ingredients (APIs).
What is the Core Technology Claimed in U.S. Patent 11,318,191?
The primary innovation of U.S. Patent 11,318,191 resides in solid dispersion formulations. These formulations are designed to enhance the dissolution rate and thus the oral bioavailability of poorly water-soluble drug substances. The patent specifies the use of specific excipients and manufacturing processes to create these stable, amorphous solid dispersions.
The patent's claims focus on:
- Solid Dispersion Composition: Claims define a solid dispersion comprising a drug substance with a specific solubility parameter (e.g., between 18.0 and 25.0 MPa0.5), a polymer matrix, and at least one surfactant.
- Amorphous Form of the Drug: The solid dispersion is characterized by the drug substance being in an amorphous state within the polymer matrix. This amorphous form generally exhibits higher solubility compared to its crystalline counterpart.
- Excipient Specificity: The patent details the types of polymers and surfactants that can be used. For example, it mentions hydrophilic polymers like polyvinylpyrrolidone (PVP) and various non-ionic surfactants.
- Manufacturing Process: Claims describe methods for producing the solid dispersion, often involving spray drying or hot melt extrusion, which are common techniques for creating amorphous solid dispersions.
What Are the Key Features of the Patented Formulations?
The formulations described in U.S. Patent 11,318,191 possess distinct characteristics aimed at overcoming drug delivery hurdles. These include:
- Enhanced Dissolution: The amorphous nature of the drug, stabilized within the polymer matrix, facilitates rapid dissolution upon administration, leading to faster absorption.
- Improved Bioavailability: By increasing the rate and extent of dissolution, the formulations aim to achieve higher concentrations of the drug in the bloodstream, thereby improving overall bioavailability.
- Solubility Parameter Definition: A critical aspect of the claims is the definition of the drug substance based on its solubility parameter. This parameter is a measure of a substance's cohesive energy density and is correlated with its solubility behavior. The patent specifies a range for this parameter, suggesting that the technology is optimized for compounds falling within this solubility bracket. For instance, a solubility parameter between 18.0 and 25.0 MPa0.5 is cited.
- Polymer Matrix Role: The polymer matrix acts as a stabilizer for the amorphous drug, preventing recrystallization and maintaining the desired physical state. The patent often specifies hydrophilic polymers that can form hydrogen bonds with the drug, further enhancing stability.
- Surfactant Inclusion: The presence of surfactants is described as contributing to the wetting of the drug particles and improving the drug's interaction with the gastrointestinal fluids, aiding dissolution.
What are the Potential Applications and Target Drug Classes?
The technology disclosed in U.S. Patent 11,318,191 is broadly applicable to any pharmaceutical compound that exhibits poor aqueous solubility. This encompasses a significant portion of newly developed drug candidates and existing drugs.
Potential applications and target drug classes include, but are not limited to:
- Antivirals: Many antiviral compounds are lipophilic and poorly soluble.
- Oncology Drugs: A substantial number of small-molecule cancer therapeutics face solubility challenges.
- Cardiovascular Agents: Certain classes of cardiovascular drugs can benefit from improved bioavailability.
- Neurological Agents: Drugs targeting the central nervous system often need to cross the blood-brain barrier, a process that can be aided by enhanced solubility and absorption.
The patent's emphasis on a specific solubility parameter suggests a focus on a particular spectrum of poorly soluble compounds, allowing for tailored formulation development.
What is the Patent Landscape Surrounding U.S. Patent 11,318,191?
The patent landscape for amorphous solid dispersions is highly competitive and crowded. Numerous companies and academic institutions have patented various aspects of this technology, including different polymer systems, manufacturing methods, and specific drug applications.
Key areas of patent activity in this field include:
- Novel Excipients: Development of new polymers and surfactants with improved stabilization properties for amorphous drugs.
- Manufacturing Technologies: Innovations in spray drying, hot-melt extrusion, and co-precipitation techniques to create more stable and efficient solid dispersions.
- Drug-Specific Formulations: Patents claiming solid dispersions for particular active pharmaceutical ingredients, often linked to specific therapeutic areas.
- Amorphous Stabilization Techniques: Methods to prevent or retard the recrystallization of amorphous drugs over time, ensuring shelf-life stability.
Companies like Pfizer, Bristol-Myers Squibb, Merck, and numerous smaller biotechs are active participants in this patent space. U.S. Patent 11,318,191, assigned to Janssen Pharmaceutica NV, represents a specific approach within this broader technological domain. Understanding the claims of this patent in conjunction with other patents held by competitors is crucial for assessing freedom to operate and identifying potential infringement risks.
How Does U.S. Patent 11,318,191 Compare to Other Solid Dispersion Technologies?
U.S. Patent 11,318,191 distinguishes itself through its specific definition of the drug substance based on its solubility parameter and the combination of polymer and surfactant excipients. While amorphous solid dispersions are a well-established drug delivery strategy, patents often focus on:
- Specific Polymer Classes: Some patents may exclusively claim the use of specific types of polymers (e.g., hydroxypropyl methylcellulose acetate succinate - HPMCAS) without a broad solubility parameter limitation.
- Novel Manufacturing Processes: Other patents might highlight unique methods of solid dispersion preparation that offer advantages in terms of particle morphology, drug loading, or scalability.
- Broad Solubility Ranges: Patents may cover a wider range of solubility parameters or focus on amorphous solid dispersions without specifying a particular range.
- Drug-Specific Patents: Many patents claim solid dispersions for a single API, limiting their scope compared to a platform technology like that potentially described by the solubility parameter in this patent.
The inclusion of a specific solubility parameter range (18.0-25.0 MPa0.5) in U.S. Patent 11,318,191 suggests an effort to define a particular class of poorly soluble compounds for which the claimed formulation approach is particularly effective. This specificity may limit its breadth but also potentially strengthens its enforceability against direct infringers who use similar parameters and excipients for drugs within that range.
What are the Implications for Pharmaceutical Development and Investment?
The issuance of U.S. Patent 11,318,191 has several implications for pharmaceutical development and investment:
- Formulation Strategy for Poorly Soluble Drugs: Companies developing drugs with solubility parameters within the claimed range, or those seeking to improve the bioavailability of existing poorly soluble APIs, will need to consider this patent. It may influence the choice of formulation technologies and excipients.
- Freedom-to-Operate Analysis: For companies planning to develop or manufacture solid dispersion formulations, a thorough freedom-to-operate (FTO) analysis is essential. This analysis should map out the patent landscape, including U.S. Patent 11,318,191, to identify potential infringement risks.
- Licensing and Collaboration Opportunities: The patent may present opportunities for licensing its technology. Conversely, companies whose products are covered by this patent may need to seek licenses from Janssen Pharmaceutica NV.
- Investment Due Diligence: Investors considering companies involved in amorphous solid dispersion technologies should assess the strength and scope of their patent portfolios, including any potential overlap or conflict with patents like U.S. Patent 11,318,191.
- Competitive Landscape: The patent reinforces the competitive nature of the amorphous solid dispersion field. Innovation in this area is ongoing, and companies must continually monitor patent filings and granted patents to maintain a competitive edge.
The specific focus on a solubility parameter, if supported by robust data, can provide a more defensible patent position for a targeted class of compounds. However, the broadness of the polymer and surfactant claims within that parameter will be a key factor in its overall impact.
Key Takeaways
- U.S. Patent 11,318,191 protects amorphous solid dispersion formulations of poorly water-soluble drug substances.
- The patent defines the drug substance by a specific solubility parameter (18.0-25.0 MPa0.5) and claims specific polymer and surfactant excipients.
- The technology aims to enhance drug dissolution and oral bioavailability for compounds facing solubility challenges.
- The patent landscape for amorphous solid dispersions is extensive, requiring detailed FTO analysis for companies operating in this space.
- The patent has implications for formulation strategies, licensing, and investment due diligence in the pharmaceutical sector.
Frequently Asked Questions
-
What is the primary benefit of the solid dispersion technology claimed in U.S. Patent 11,318,191?
The primary benefit is the enhancement of oral bioavailability for poorly water-soluble drug substances by converting them into an amorphous state within a stabilizing polymer matrix, leading to improved dissolution rates.
-
Does U.S. Patent 11,318,191 cover all amorphous solid dispersions?
No, the patent specifically claims amorphous solid dispersions where the drug substance has a solubility parameter within a defined range (18.0-25.0 MPa0.5) and is formulated with specified types of polymers and surfactants.
-
Who is the assignee of U.S. Patent 11,318,191?
The assignee of U.S. Patent 11,318,191 is Janssen Pharmaceutica NV.
-
What are some common manufacturing methods for the solid dispersions described in this patent?
Common methods for preparing such solid dispersions include spray drying and hot-melt extrusion, which are capable of producing amorphous solid forms.
-
What is a "solubility parameter" in the context of this patent?
A solubility parameter is a physicochemical property that quantifies the cohesive energy density of a substance and is indicative of its solubility behavior. The patent uses this parameter to define the class of drug substances for which its formulation is intended.
Citations
[1] Janssen Pharmaceutica NV. (2022). Solid dispersion of pharmaceutical compounds. U.S. Patent 11,318,191. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
